Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000650 · ClinicalTrials.gov registry record · NA
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00000650 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants.
The verdict
NCT00000650, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine, in HIV-infected patients, the magnitude and duration of the biological effects of ditiocarb sodium (sodium diethyldithiocarbamate; DTC) that may be relevant to treatment of HIV infection. DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion of delay in disease progression to AIDS and improvement in CD4 counts while on the drug.
Interventions
- DRUG Ditiocarb sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Est. Completion | 1996-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000650
The ClinicalTrials.gov registry entry for NCT00000650 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ditiocarb sodium is the first listed.
NCT00000650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000650 about?
NCT00000650 is a clinical study titled "An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients". To determine, in HIV-infected patients, the magnitude and duration of the biological effects of ditiocarb sodium (sodium diethyldithiocarbamate; DTC) that may be relevant to treatment of HIV infection. DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion of ...
What is the current status of trial NCT00000650?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. Estimated completion is 1996-09.
What interventions are being tested in trial NCT00000650?
The interventions under investigation include: Ditiocarb sodium (DRUG).
Who is sponsoring clinical trial NCT00000650?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.